Published in MAbs on January 01, 2011
A strategy for risk mitigation of antibodies with fast clearance. MAbs (2013) 1.42
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med (2012) 1.14
Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J (2012) 1.05
Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One (2013) 1.03
Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. MAbs (2014) 0.94
Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. MAbs (2012) 0.93
Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood (2014) 0.86
From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. J Natl Cancer Inst (2013) 0.82
Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. AAPS J (2014) 0.82
Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research. Br J Clin Pharmacol (2015) 0.82
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs (2016) 0.82
A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design. MAbs (2014) 0.81
Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics. J Biol Chem (2015) 0.79
Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice. MAbs (2014) 0.79
Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry. Drug Metab Dispos (2014) 0.78
Allometry of factor VIII and informed scaling of next-generation therapeutic proteins. J Pharm Sci (2013) 0.78
Anti-infective immunoadhesins from plants. Plant Biotechnol J (2015) 0.78
Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo. Sci Rep (2016) 0.77
Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies. AAPS J (2013) 0.77
Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug disposition. CPT Pharmacometrics Syst Pharmacol (2014) 0.77
Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding. MAbs (2016) 0.77
Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies. MAbs (2013) 0.76
Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice. MAbs (2016) 0.76
Pharmacokinetics and biodistribution of a human monoclonal antibody to oxidized LDL in cynomolgus monkey using PET imaging. PLoS One (2012) 0.76
Integrated Two-Analyte Population Pharmacokinetic Model for Antibody-Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
Population Pharmacokinetics of Necitumumab in Cancer Patients. Clin Pharmacokinet (2016) 0.75
Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics. MAbs (2016) 0.75
Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer. Oncotarget (2014) 0.75
Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas. PLoS One (2016) 0.75
Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model. Pharm Res (2015) 0.75
Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in Mice. AAPS J (2015) 0.75
Population physiologically-based pharmacokinetic model incorporating lymphatic uptake for a subcutaneously administered pegylated peptide. In Silico Pharmacol (2016) 0.75
Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, ExtendedHalf-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrob Agents Chemother (2016) 0.75
Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys. MAbs (2015) 0.75
Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. Pharm Res (2014) 0.75
Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates. MAbs (2017) 0.75
Physiological parameters in laboratory animals and humans. Pharm Res (1993) 8.14
Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (2008) 4.17
The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J Exp Biol (2005) 3.30
Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol (2001) 2.87
Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet (2010) 2.20
To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol (2009) 2.07
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther (1999) 1.88
Role of fixed coefficients and exponents in the prediction of human drug clearance: how accurate are the predictions from one or two species? J Pharm Sci (2009) 1.53
Animal scale-up. J Pharmacokinet Biopharm (1973) 1.29
Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev (1984) 1.26
Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol (2009) 1.15
Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos (2010) 1.14
Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica (1996) 1.07
Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci (2009) 0.99
Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci (2004) 0.97
Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol (2006) 0.96
A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci (2006) 0.94
Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys. Pharm Res (2007) 0.93
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. Int Immunopharmacol (2008) 0.93
Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable? Biopharm Drug Dispos (2004) 0.86
Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection. Drug Metab Dispos (2005) 0.84
Pharmacokinetic scaling of bisphenol A by species-invariant time methods. Xenobiotica (2002) 0.82
Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med (2011) 2.51
Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev (2002) 2.29
Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther (2012) 2.03
A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med (2011) 1.75
Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci (2002) 1.58
Enhanced tumor retention of a radiohalogen label for site-specific modification of antibodies. J Med Chem (2013) 1.49
Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci (2002) 1.44
A strategy for risk mitigation of antibodies with fast clearance. MAbs (2013) 1.42
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res (2009) 1.41
Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem (2011) 1.40
Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos (2010) 1.38
An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci (2012) 1.36
Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem (2010) 1.32
Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol (2010) 1.27
Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res (2006) 1.26
Heme oxygenase-1 overexpression protects rat hearts from cold ischemia/reperfusion injury via an antiapoptotic pathway. Transplantation (2002) 1.25
Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol (2012) 1.25
Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J (2012) 1.20
Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res (2012) 1.17
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem (2010) 1.15
Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab Dispos (2004) 1.13
Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse. J Immunol (2003) 1.12
Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet (2011) 1.09
Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol (2008) 1.06
Gene transfer of heme oxygenase-1 and carbon monoxide delivery inhibit chronic rejection. Am J Transplant (2002) 1.04
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood (2007) 1.01
Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol Cancer Ther (2008) 1.01
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn (2010) 0.97
Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med (2013) 0.97
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem (2012) 0.96
Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. MAbs (2012) 0.96
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther (2013) 0.94
Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos (2005) 0.93
Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J (2012) 0.92
Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol (2012) 0.92
Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci (2003) 0.90
Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model. J Invest Dermatol (2005) 0.90
Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology. Ther Deliv (2011) 0.89
Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. PLoS One (2011) 0.89
Delivery of tea polyphenols to the oral cavity by green tea leaves and black tea extract. Cancer Epidemiol Biomarkers Prev (2004) 0.89
Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states. Mol Pharm (2013) 0.88
Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues. Mol Pharm (2014) 0.88
Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem (2008) 0.86
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine. J Med Chem (2004) 0.86
Development and evaluation of a novel method for preclinical measurement of tissue vascular volume. Mol Pharm (2010) 0.85
Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the Hedgehog pathway inhibitor GDC-0449 in dogs: an investigation using preclinical studies and physiologically based pharmacokinetic modeling. Drug Metab Dispos (2010) 0.85
Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci (2009) 0.84
Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey. Eur J Pharm Sci (2013) 0.83
Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett (2010) 0.82
Drug delivery across the blood-brain barrier. Mol Pharm (2013) 0.81
Current challenges and opportunities in nonclinical safety testing of biologics. Drug Discov Today (2013) 0.81
Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett (2010) 0.81
Sustained delivery of human growth hormone from a novel gel system: SABER. Biomaterials (2002) 0.80
Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans. Pharm Res (2012) 0.80
Evidence for an asialoglycoprotein receptor on nonparenchymal cells for O-linked glycoproteins. J Pharmacol Exp Ther (2008) 0.79
Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components. J Pharmacokinet Pharmacodyn (2011) 0.79
RDP58, a novel immunomodulatory peptide, ameliorates clinical signs of disease in the Lewis rat model of acute experimental autoimmune encephalomyelitis. J Neuroimmunol (2004) 0.78
A hybrid approach to advancing quantitative prediction of tissue distribution of basic drugs in human. Toxicol Appl Pharmacol (2010) 0.78
Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys. Pharm Res (2014) 0.78
Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model. J Pharmacokinet Pharmacodyn (2012) 0.76
Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies. MAbs (2013) 0.76
An algorithm for evaluating potential tissue drug distribution in toxicology studies from readily available pharmacokinetic parameters. J Pharm Sci (2013) 0.75
Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in mice. Pharm Res (2012) 0.75
Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58. Transpl Int (2003) 0.75
Vascular physiology and protein disposition in a preclinical model of neurodegeneration. Mol Pharm (2013) 0.75
Highlights from a recent BIO survey on therapeutic protein-drug interactions. J Clin Pharmacol (2011) 0.75
Influence of the compound selection process on the performance of human clearance prediction methods. J Pharm Sci (2011) 0.75